Modified Pulsatillae decoction inhibits DSS-induced ulcerative colitis in vitro and in vivo via IL-6/STAT3 pathway
Authors: Artur Jurczyszyn
Ye Yang
Bin Jiang
Renjie Dou
Mengjie Guo
Shaohua Huangfu
Sixia Zhong
Chunyan Gu
Journal: BMC Complementary Medicine and Therapies (2020)
Discipline: CLINICAL MEDICINE
Keywords: DSS; IL-6/STAT3 pathway; Modified Pulsatillae decoction; NCM460; Ulcerative colitis.
Affiliations: Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China., School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China., Department of Hematology, Jagiellonian University Medical College, 30-051, Cracow, Poland., Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China. ., Laboratory for Combination of Acupuncture and Chinese Materia Medica of Chinese Ministry of Education, Nanjing University of Chinese Medicine, Nanjing, China. .

Abstract:  Background: Ulcerative colitis (UC) is a chronic inflammatory disorder of the colon and rectum, which is positively correlated with the occurrence of IBD-related colorectal cancer (IBD-CRC). Conventional therapies based on drugs such as corticosteroids, mesalamine, and immunosuppression have serious side effects. Pulsatillae decoction (PD) served as a classical prescription for the treatment of colitis in China, has been shown to exert prominent curative effects and good safety. Based on clinical experience and our amelioration, we added an extra herb into this classical prescription, but its therapeutic effect on UC and the underlying mechanism are still unclear. Results: We first found the curative effect of modified PD on dextran sodium sulfate (DSS)-incubated NCM460 cells. Then C57BL/6 mice were administered DSS to induce UC to evaluate the therapeutic of modified PD. The results showed that modified PD alleviated the inflammatory injury, manifested in body weight, colon length, and disease activity index, with histological analysis of colon injury. Transcriptomic sequencing indicated that modified PD treatment downregulated the IL-6/STAT3 signaling pathway, and reduced the levels of p-NF-κB, IL-1β and NLRP3, which were confirmed by western blot. Conclusions: Collectively, our results indict that modified PD could efficiently relieve clinical signs and inflammatory mediators of UC, providing evidence of the anti-colitis effect of modified PD, which might provide novel strategies for therapeutic intervention in UC, which may be applied to the prevention of IBD-CRC. 

Retracted: No

PubPeer comments:
 Bioscience Reports (2018) 38(5); https: doi.org 10.1042 BSR20180479 The authors are retracting their published article as they have found that their conclusions linking C14orf166 expression to prognosis were not consistent with the Human Protein Atlas data (available at https: www.proteinatlas.org ENSG00000087302-C14orf166 pathology tissue lung+cancer). This may be due to differences in sample ethnicity, and the small sample size used in their study. Due to this discrepancy, the authors believe that the results of the retracted article may not be representative of the Chinese lung cancer population. The authors apologise for any inconvenience caused to the readers. u00a92019The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 1 Downloaded from https: portlandpress.com bio ,